Comparable stake leader
FARALLON CAPITAL MANAGEMENT, L.L.C.
SEC ownership of Crinetics Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001658247.
Disclosed value leader
FARALLON CAPITAL MANAGEMENT, L.L.C.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CRNX on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FARALLON CAPITAL MANAGEMENT, L.L.C.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FARALLON CAPITAL MANAGEMENT, L.L.C.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001658247
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Crinetics Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FARALLON CAPITAL MANAGEME...
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 8.5%
13D/G row: FARALLON CAPITAL MANAGEMENT, L.L.C.
Showing 1-8 of 50 holder rows.
Quick read
FARALLON CAPITAL MANAGEMENT, L.L.C. leads the comparable SEC ownership view at 8.5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FARALLON CAPITAL MANAGEMENT, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
FARALLON CAPITAL MANAGEMENT, L.L.C.
8.5%
Farallon Capital Partners, L.P.
8.5%
WELLINGTON MANAGEMENT GROUP LLP
7.8%
DRIEHAUS CAPITAL MANAGEMENT LLC
6.1%
VANGUARD CAPITAL MANAGEMENT LLC
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
8.5%
|
$752,117,830
8,989,098 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.5%
|
$373,521,762
8,024,098 shares
|
+$111,673,450 | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
7.8%
|
$321,720,126
8,157,204 shares
|
-$8,865,599 | 31 Mar 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
6.1%
|
$252,255,164
6,395,922 shares
|
$0 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$197,604,263
5,440,646 shares
|
$0 | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
5.1%
|
$211,201,634
5,355,011 shares
|
$0 | 31 Mar 2026 |
| FMR LLC |
13F
13D/G
Company
|
1.4%
from 13D/G
|
$572,395,895
15,759,799 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
8.2%
|
$307,950,573
8,478,815 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$8,879,588.
Buys
$0
Insiders: 0
Sells
$8,879,588
Insiders: 9
Net
-$8,879,588
Shares: -231,272
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 231,272
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 9,900 | $0 | $366,143 | -$366,143 |
| 3-6 | 0 | 142,380 | $0 | $5,569,647 | -$5,569,647 |
| 6-9 | 0 | 7,500 | $0 | $362,600 | -$362,600 |
| 9-12 | 0 | 71,492 | $0 | $2,581,199 | -$2,581,199 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Crinetics Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
PERCEPTIVE ADVISORS LLC
Net 12M change
-$8,879,589
Latest report
02 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10%+ Owner | $200,336,855 | Mixed | 18 Apr 2022 | ||
| Richard Scott Struthers | President & CEO, Director | $50,229,941 | -$1,001,513 | -2% | Mixed | 29 May 2026 |
| Ajay Madan | Chief Development Officer | $7,783,510 | Mixed | 28 Feb 2022 | ||
| Stephen F. Betz | Chief Scientific Officer | $5,178,304 | -$396,610 | -7.1% | Filing P/S | 16 Mar 2026 |
| Wendell Wierenga | Director | $4,433,618 | Mixed | 18 Jun 2026 | ||
| Jeff E. Knight | Chief Dev. & Operating Officer | $4,222,088 | -$3,785,448 | -47% | Filing P/S | 08 Apr 2026 |
| Wendall Wierenga | Director | $3,869,984 | Mixed | 11 Jun 2025 | ||
| Tobin Schilke | Chief Financial Officer | $3,099,060 | -$266,305 | -7.9% | Filing P/S | 03 Mar 2026 |
| Dana Pizzuti | Chief Med and Dev Officer | $3,009,001 | -$1,910,299 | -39% | Filing P/S | 01 Dec 2025 |
| Isabel Kalofonos | Chief Commercial Officer | $1,939,905 | -$137,500 | -6.6% | Mixed | 23 Feb 2026 |
| Marc Wilson | Cfo | $1,671,244 | Mixed | 31 Dec 2024 | ||
| Alan Seth Krasner | Chief Medical Officer | $1,626,857 | Mixed | 17 Oct 2023 | ||
| James Hassard | Chief Commercial Officer | $1,289,737 | Filing P/S | 05 Jul 2024 | ||
| Matthew K. Fust | Director | $1,044,599 | -$716,000 | -41% | Mixed | 18 Jun 2026 |
| Camille L. Bedrosian | Director | $807,212 | Mixed | 18 Jun 2026 | ||
| Weston Nichols | Director | $807,212 | Mixed | 18 Jun 2026 | ||
| Caren Deardorf | Director | $807,212 | Mixed | 18 Jun 2026 | ||
| Coelho Rogerio Vivaldi | Director | $769,000 | -$300,761 | -28% | Filing P/S | 02 Jul 2026 |
| Stephanie Okey | Director | $447,644 | -$365,153 | -45% | Mixed | 18 Jun 2026 |
Recent insider transactions for Crinetics Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Coelho Rogerio Vivaldi | CRNX | Common Stock | Sale | -13.5% | $120,000 | $40.00 | -3,000 | 19,225 | 02 Jul 2026 | Direct |
| Caren Deardorf | CRNX | Common Stock | Award | 36.4% | 5,925 | 22,225 | 18 Jun 2026 | Direct | ||
| Caren Deardorf | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Matthew K. Fust | CRNX | Common Stock | Award | 26% | 5,925 | 28,761 | 18 Jun 2026 | Direct | ||
| Matthew K. Fust | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Weston Nichols | CRNX | Common Stock | Award | 36.4% | 5,925 | 22,225 | 18 Jun 2026 | Direct | ||
| Weston Nichols | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Coelho Rogerio Vivaldi | CRNX | Common Stock | Award | 36.4% | 5,925 | 22,225 | 18 Jun 2026 | Direct | ||
| Coelho Rogerio Vivaldi | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Camille L. Bedrosian | CRNX | Common Stock | Award | 36.4% | 5,925 | 22,225 | 18 Jun 2026 | Direct | ||
| Camille L. Bedrosian | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Wendell Wierenga | CRNX | Common Stock | Award | 5.1% | 5,925 | 122,071 | 18 Jun 2026 | Direct | ||
| Wendell Wierenga | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Stephanie Okey | CRNX | Common Stock | Award | 92.6% | 5,925 | 12,325 | 18 Jun 2026 | Direct | ||
| Stephanie Okey | CRNX | Stock Option (Right to Buy) | Award | 9,730 | 9,730 | 18 Jun 2026 | Direct | |||
| Stephanie Okey | CRNX | Common Stock | Sale | -51.9% | $246,143 | $35.67 | -6,900 | 6,400 | 17 Jun 2026 | Direct |
| Richard Scott Struthers | CRNX | Common Stock | Gift | 111,100 | 111,100 | 29 May 2026 | By Family Trust 8 | |||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 111,100 | 111,100 | 29 May 2026 | By Family Trust 7 | |||
| Richard Scott Struthers | CRNX | Common Stock | Gift | -99.6% | -222,200 | 1,000 | 29 May 2026 | By Spouse | ||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 111,100 | 111,100 | 29 May 2026 | By Family Trust 6 | |||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 111,100 | 111,100 | 29 May 2026 | By Family Trust 5 | |||
| Richard Scott Struthers | CRNX | Common Stock | Gift | -35.4% | -222,200 | 404,778 | 29 May 2026 | Direct | ||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 80,000 | 80,000 | 29 May 2026 | By Charitable Trust | |||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 22220% | 222,200 | 223,200 | 29 May 2026 | By Spouse | ||
| Richard Scott Struthers | CRNX | Common Stock | Gift | 54.9% | 222,200 | 626,978 | 29 May 2026 | Direct | ||
| Richard Scott Struthers | CRNX | Common Stock | Gift | -79.3% | -524,400 | 136,805 | 29 May 2026 | By Family Trust 1 | ||
| Jeff E. Knight | CRNX | Common Stock | Sale | -44.7% | $3,415,036 | $40.10 | -85,163 | 105,289 | 08 Apr 2026 | Direct |
| Jeff E. Knight | CRNX | Common Stock | Options Exercise | 70% | 78,434 | 190,452 | 08 Apr 2026 | Direct | ||
| Jeff E. Knight | CRNX | Stock Option (Right to Buy) | Options Exercise | -88.1% | -78,434 | 10,589 | 08 Apr 2026 | Direct | ||
| Jeff E. Knight | CRNX | Common Stock | Sale | -8.13% | $370,411 | $37.37 | -9,911 | 112,018 | 16 Mar 2026 | Direct |
| Stephen F. Betz | CRNX | Common Stock | Sale | -7.18% | $396,610 | $37.37 | -10,612 | 137,101 | 16 Mar 2026 | Direct |
| Richard Scott Struthers | CRNX | Common Stock | Sale | -5.15% | $821,513 | $37.37 | -21,981 | 404,778 | 16 Mar 2026 | Direct |
| Coelho Rogerio Vivaldi | CRNX | Common Stock | Sale | -23.5% | $180,761 | $36.15 | -5,000 | 16,300 | 12 Mar 2026 | Direct |
| Stephanie Okey | CRNX | Common Stock | Sale | -18.4% | $119,010 | $39.67 | -3,000 | 13,300 | 03 Mar 2026 | Direct |
| Tobin Schilke | CRNX | Common Stock | Sale | -7.91% | $266,305 | $39.67 | -6,713 | 78,121 | 03 Mar 2026 | Direct |
| Richard Scott Struthers | CRNX | Common Stock | Award | 17% | 62,000 | 426,759 | 23 Feb 2026 | Direct | ||
| Richard Scott Struthers | CRNX | Stock Option (Right to Buy) | Award | 228,000 | 228,000 | 23 Feb 2026 | Direct | |||
| Tobin Schilke | CRNX | Common Stock | Award | 60.6% | 32,000 | 84,834 | 23 Feb 2026 | Direct | ||
| Tobin Schilke | CRNX | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 23 Feb 2026 | Direct | |||
| Jeff E. Knight | CRNX | Common Stock | Award | 38.7% | 34,000 | 121,929 | 23 Feb 2026 | Direct | ||
| Jeff E. Knight | CRNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 23 Feb 2026 | Direct | |||
| Stephen F. Betz | CRNX | Common Stock | Award | 25.5% | 30,000 | 147,713 | 23 Feb 2026 | Direct | ||
| Stephen F. Betz | CRNX | Stock Option (Right to Buy) | Award | 47,000 | 47,000 | 23 Feb 2026 | Direct | |||
| Isabel Kalofonos | CRNX | Common Stock | Award | 4076.7% | 34,000 | 34,834 | 23 Feb 2026 | Direct | ||
| Isabel Kalofonos | CRNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 23 Feb 2026 | Direct | |||
| Isabel Kalofonos | CRNX | Common Stock | Sale | -75% | $137,500 | $55.00 | -2,500 | 834 | 05 Jan 2026 | Direct |
| Isabel Kalofonos | CRNX | Common Stock | Options Exercise | 299.8% | 2,500 | 3,334 | 05 Jan 2026 | Direct | ||
| Isabel Kalofonos | CRNX | Stock Option (Right to Buy) | Options Exercise | -2.5% | -2,500 | 97,500 | 05 Jan 2026 | Direct | ||
| Stephen F. Betz | CRNX | Common Stock | Options Exercise | 18% | 18,000 | 117,713 | 26 Dec 2025 | Direct | ||
| Stephen F. Betz | CRNX | Stock Option (Right to Buy) | Options Exercise | -16.6% | -18,000 | 90,514 | 26 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.